Boston QSP May 2019 Event Announcement
Boston- Please join us on Wednesday, May 15th, 2019 for our regular bimonthly event series "QSP in Drug Development" hosted by Boston QSP Inc. The event will feature a presentation titled “Merging Human-relevant in-vitro Models with Quantitative Systems Pharmacology” by the distinguished guest speaker Dr. Murat Cirit from MIT. The talk will be followed by a mixer and reception where attendees enjoy great company and conversation with fellow community members over selected craft beers and pizza from a local small business.
Registration is free but RSVP is required. The event is sponsored by Novartis. The Cambridge Innovation Center (CIC) is the venue sponsor.
5:00-5:30 PM: Registration (outside Havana Room)
5:30-6:20 PM: Presentation and Q&A. Presentation title: “Merging Human-relevant in-vitro Models with Quantitative Systems Pharmacology” (Havana Room)
6:20-7:30 PM: Mixer & Reception (Venture Café, a few steps down the hallway from the Havana room)
Venue: Cambridge Innovation Center, 1 Broadway, Cambridge.
RSVP here. Limited seats.
* Please do not hesitate to RSVP on the waiting list if the RSVP is full as some guests "un-RSVP" as the event gets closer.
Murat Cirit, PhD is the principal investigator of Translational Center of Tissue Chip Technologies (TC2T) at MIT and the founder of Javelin Biotech. He brings an interdisciplinary and systematic approach combining experimental knowledge and computational modeling to deeper understanding of biological, physiological, and physical processes. His main research focuses on drug discovery, applied tissue engineering, and computational biology (quantitative systems pharmacology and systems biology).
A large percentage of drug candidates fail at the clinical trial stage due to a lack of efficacy and unacceptable toxicity, primarily because of translational gap between human physiology and preclinical models including both in vitro culture and animal models. This need for more human-physiology relevant in vitro systems for preclinical efficacy and toxicity testing has led to a major effort to develop “Microphysiological Systems (MPS)”, aka tissue chips (TC) or organs on chips (OOC), based on engineered human tissue constructs. Microphysiological systems hold promise for improving therapeutic drug approval rates by providing more physiological, human-based, in vitro assays for preclinical drug development activities compared to traditional in vitro and animal models. The full impact of MPS technologies will be realized only when robust approaches for in vitro–in vivo (MPS-to-human) translation are developed and utilized, and explain how the burgeoning field of quantitative systems pharmacology (QSP) can fill that need.
About Boston QSP
Boston QSP is a 501(c)(3) non-profit organization whose mission is to foster the sharing of QSP knowledge, challenges, solutions, and opportunities to advance the field as an interdisciplinary community in Boston.